Are incentives necessary to achieve trial diversity? Two researchers say yes
Pharma companies and even Congress have made efforts over the last year to ensure clinical trials are more representative of the patients they serve — but two researchers argue that isn’t enough.
Brigham and Women’s urologist Thomas Hwang and John’s Hopkins oncology professor Otis Brawley opined in a New England Journal of Medicine piece on Saturday that achieving diversity in clinical trials will take a combination of federal incentives and regulations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.